<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://latebreakingscience.com/wp-content/plugins/seriously-simple-podcasting/templates/feed-stylesheet.xsl"?><rss version="2.0"
	 xmlns:content="http://purl.org/rss/1.0/modules/content/"
	 xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	 xmlns:dc="http://purl.org/dc/elements/1.1/"
	 xmlns:atom="http://www.w3.org/2005/Atom"
	 xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	 xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	 xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
	 xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0"
	 xmlns:podcast="https://podcastindex.org/namespace/1.0"
	>
		<channel>
		<title>Late Breaking Science</title>
		<atom:link href="https://latebreakingscience.com/feed/podcast/late-breaking-science/" rel="self" type="application/rss+xml"/>
		<link>https://latebreakingscience.com/series/late-breaking-science/</link>
		<description>Latest conference highlights</description>
		<lastBuildDate>Thu, 20 Nov 2025 14:00:44 +0000</lastBuildDate>
		<language>en-US</language>
		<copyright>© 2019 Late Breaking Science</copyright>
		<itunes:subtitle>Late Breaking Science</itunes:subtitle>
		<itunes:author>Late Breaking Science</itunes:author>
		<itunes:summary>Latest conference highlights</itunes:summary>
		<itunes:owner>
			<itunes:name>Late Breaking Science</itunes:name>
			<itunes:email>info@graphical-media.com</itunes:email>
		</itunes:owner>
		<itunes:explicit>false</itunes:explicit>
		<itunes:image href="https://latebreakingscience.com/wp-content/uploads/2019/02/Late_Breaking_Science_cover-video-capsules.svg"></itunes:image>
			<image>
				<url>https://latebreakingscience.com/wp-content/uploads/2019/02/Late_Breaking_Science_cover-video-capsules.svg</url>
				<title>Late Breaking Science</title>
				<link>https://latebreakingscience.com/series/late-breaking-science/</link>
			</image>
		<googleplay:author><![CDATA[Late Breaking Science]]></googleplay:author>
			<googleplay:email>info@graphical-media.com</googleplay:email>			<googleplay:description>Latest conference highlights</googleplay:description>
			<googleplay:explicit>No</googleplay:explicit>
			<googleplay:image href="https://latebreakingscience.com/wp-content/uploads/2019/02/Late_Breaking_Science_cover-video-capsules.svg"></googleplay:image>
			<podcast:locked owner="info@graphical-media.com">yes</podcast:locked>
		<podcast:guid>d3950bb6-dc55-5f85-8551-91121e3b02c6</podcast:guid>
		
		<!-- podcast_generator="SSP by Castos/3.15.0" Seriously Simple Podcasting plugin for WordPress (https://wordpress.org/plugins/seriously-simple-podcasting/) -->
		<generator>https://wordpress.org/?v=6.9.4</generator>

<item>
	<title>Dr. Michael Ong</title>
	<link>https://latebreakingscience.com/podcast/dr-michael-ong-5000-5002/</link>
	<pubDate>Fri, 11 Jun 2021 13:36:03 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=531</guid>
	<description><![CDATA[Abstract 5000: A phase 3 trial with a 2&#215;2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novometastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1. Abstract 5002: Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated ... <a title="Dr. Michael Ong" class="read-more" href="https://latebreakingscience.com/podcast/dr-michael-ong-5000-5002/" aria-label="Read more about Dr. Michael Ong">Read more</a>]]></description>
	<itunes:subtitle><![CDATA[Abstract 5000: A phase 3 trial with a 2&#215;2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novometastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1. Abstract 5002: Decrease]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract 5000: A phase 3 trial with a 2&#215;2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novometastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1. Abstract 5002: Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated ... <a title="Dr. Michael Ong" class="read-more" href="https://latebreakingscience.com/podcast/dr-michael-ong-5000-5002/" aria-label="Read more about Dr. Michael Ong">Read more</a>]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/531/dr-michael-ong-5000-5002.mp3" length="24773348" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract 5000: A phase 3 trial with a 2&#215;2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novometastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1. Abstract 5002: Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated ... Read more]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>12:54</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract 5000: A phase 3 trial with a 2&#215;2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novometastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1. Abstract 5002: Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated ... Read more]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Steven Yip</title>
	<link>https://latebreakingscience.com/podcast/dr-steven-yip-lba4-5055/</link>
	<pubDate>Fri, 11 Jun 2021 13:35:06 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=530</guid>
	<description><![CDATA[Abstract LBA4: Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).]]></description>
	<itunes:subtitle><![CDATA[Abstract LBA4: Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract LBA4: Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/530/dr-steven-yip-lba4-5055.mp3" length="16356486" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract LBA4: Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>8:31</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract LBA4: Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Anupam Batra</title>
	<link>https://latebreakingscience.com/podcast/dr-anupam-batra-5068-5046/</link>
	<pubDate>Fri, 11 Jun 2021 13:32:50 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=527</guid>
	<description><![CDATA[Abstract 5046: ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).]]></description>
	<itunes:subtitle><![CDATA[Abstract 5046: ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract 5046: ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/527/dr-anupam-batra-5068-5046.mp3" length="11221440" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract 5046: ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>5:51</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract 5046: ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Lucia Nappi</title>
	<link>https://latebreakingscience.com/podcast/dr-lucia-nappi-5020/</link>
	<pubDate>Fri, 11 Jun 2021 13:27:58 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=525</guid>
	<description><![CDATA[Abstract 5020: Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.]]></description>
	<itunes:subtitle><![CDATA[Abstract 5020: Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract 5020: Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/525/dr-lucia-nappi-5020.mp3" length="11353515" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract 5020: Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>5:55</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract 5020: Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Claudio Jeldres</title>
	<link>https://latebreakingscience.com/podcast/dr-claudio-jeldres-5072/</link>
	<pubDate>Fri, 11 Jun 2021 13:21:58 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=522</guid>
	<description><![CDATA[Abstract 5072: Real-world first-line treatment patterns in patients with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.]]></description>
	<itunes:subtitle><![CDATA[Abstract 5072: Real-world first-line treatment patterns in patients with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract 5072: Real-world first-line treatment patterns in patients with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/522/dr-claudio-jeldres-5072.mp3" length="12741139" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract 5072: Real-world first-line treatment patterns in patients with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>6:38</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract 5072: Real-world first-line treatment patterns in patients with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>
	</channel>
</rss>
